30th Jan 2014 07:00
For immediate release | 30 January 2014 |
ABCAM PLC
("Abcam" or "the Company")
Board Appointment
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of innovative protein research tools, is pleased to announce the appointment to the Board of Directors with immediate effect of Alan Hirzel, the Company's Chief Marketing Officer.
Alan, who has over 20 years of global business and leadership experience, joined Abcam in August 2013 and has responsibility for the Company's branding, product portfolio and online consumer offering.
Prior to joining Abcam, Alan spent 14 years with management consultant Bain & Company, most recently as head of the UK healthcare practice. Whilst at Bain he advised a wide range of global executives on consumer and marketing strategies to help achieve growth targets.
Mike Redmond, Abcam's Chairman, commented: "I am delighted to welcome Alan to the Board. He has a huge amount of experience relevant to our growth strategies and he is already playing a major role in their planning and execution. We very much look forward to having his input at Board level, broadening his contribution to Abcam's on-going development."
Additional Information
Alan Thomas Hirzel is age 46 years. Other than the interest in Abcam shares and the directorships/partnerships set out below, there is no further information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules.
Interest in shares: 25,104 nil cost share awards subject to the achievement of performance conditions under the Abcam plc Long Term Incentive Plan, and 214 shares held directly.
Current directorships (both not-for-profit organisations)
| Directorships / partnerships in the past five years |
The Social Business Trust The National Citizen Service Trust
| Bain & Company |
For further information please contact:
Abcam |
+ 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer
| |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield - Nominated Adviser | |
James Black - Corporate Broking | |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Andy Crossley - Corporate Broking
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.
Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 127,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices and ships to over 100 countries. The Company was founded in 1998 and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).
To find out more, please visit www.abcam.com
Related Shares:
ABC.L